Literature DB >> 32275203

Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection.

Bongiwe Ndlovu1, Kamini Gounder2, Daniel Muema3, Nagarajan Raju4, Tandile Hermanus5, Qiniso Mthethwa6, Kim Robertson7, Bruce D Walker8, Ivelin S Georgiev9, Lynn Morris10, Penny L Moore11, Thumbi Ndung'u12.   

Abstract

Broadly neutralizing antibodies (bNAbs) may constitute an essential component of a protective vaccine against HIV-1, yet no immunogen has been able to elicit them. To characterize the development of bNAbs in HIV-1 subtype C infected individuals, a panel of 18 Env-pseudotyped viruses was used to screen 18 study participants. The specificity of plasma neutralization was mapped against Env mutants and MPER chimeras. Envelope (env) gene sequence evolution was characterized by single genome amplification and sequencing. Three out of eighteen individuals developed broad plasma neutralizing activity (>60% breadth). Two of the three participants may target epitopes comprising glycans at position 276 of the D loop in the CD4 binding site and 332 glycan supersite, respectively. Deletion of these glycans was associated with neutralization resistance. Our study describes the kinetics of the development of plasma neutralizing activity and identified amino acid residue changes suggestive of immune pressure on putative epitopes. The study enhances our understanding of how neutralization breadth develops in the course of HIV-1 subtype C infection.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Broadly neutralizing antibodies; Envelope sequencing; Epitope mapping

Mesh:

Substances:

Year:  2020        PMID: 32275203      PMCID: PMC8186003          DOI: 10.1016/j.virol.2020.03.003

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  69 in total

1.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.

Authors:  Zelda Euler; Marit J van Gils; Evelien M Bunnik; Pham Phung; Becky Schweighardt; Terri Wrin; Hanneke Schuitemaker
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

3.  Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies.

Authors:  Feng Gao; Mattia Bonsignori; Hua-Xin Liao; Amit Kumar; Shi-Mao Xia; Xiaozhi Lu; Fangping Cai; Kwan-Ki Hwang; Hongshuo Song; Tongqing Zhou; Rebecca M Lynch; S Munir Alam; M Anthony Moody; Guido Ferrari; Mark Berrong; Garnett Kelsoe; George M Shaw; Beatrice H Hahn; David C Montefiori; Gift Kamanga; Myron S Cohen; Peter Hraber; Peter D Kwong; Bette T Korber; John R Mascola; Thomas B Kepler; Barton F Haynes
Journal:  Cell       Date:  2014-07-24       Impact factor: 41.582

4.  Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.

Authors:  Roger D Kouyos; Peter Rusert; Claus Kadelka; Michael Huber; Alex Marzel; Hanna Ebner; Merle Schanz; Thomas Liechti; Nikolas Friedrich; Dominique L Braun; Alexandra U Scherrer; Jacqueline Weber; Therese Uhr; Nicolas S Baumann; Christine Leemann; Herbert Kuster; Jean-Philippe Chave; Matthias Cavassini; Enos Bernasconi; Matthias Hoffmann; Alexandra Calmy; Manuel Battegay; Andri Rauch; Sabine Yerly; Vincent Aubert; Thomas Klimkait; Jürg Böni; Karin J Metzner; Huldrych F Günthard; Alexandra Trkola
Journal:  Nature       Date:  2018-09-10       Impact factor: 49.962

5.  Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection.

Authors:  Kristen Cohen; Marcus Altfeld; Galit Alter; Leonidas Stamatatos
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

6.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

7.  HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.

Authors:  Zanele Ditse; Maximilian Muenchhoff; Emily Adland; Pieter Jooste; Philip Goulder; Penny L Moore; Lynn Morris
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

8.  Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.

Authors:  Davide Corti; Johannes P M Langedijk; Andreas Hinz; Michael S Seaman; Fabrizia Vanzetta; Blanca M Fernandez-Rodriguez; Chiara Silacci; Debora Pinna; David Jarrossay; Sunita Balla-Jhagjhoorsingh; Betty Willems; Maria J Zekveld; Hanna Dreja; Eithne O'Sullivan; Corinna Pade; Chloe Orkin; Simon A Jeffs; David C Montefiori; David Davis; Winfried Weissenhorn; Aine McKnight; Jonathan L Heeney; Federica Sallusto; Quentin J Sattentau; Robin A Weiss; Antonio Lanzavecchia
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

9.  The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody.

Authors:  Sunita S Balla-Jhagjhoorsingh; Davide Corti; Leo Heyndrickx; Elisabeth Willems; Katleen Vereecken; David Davis; Guido Vanham
Journal:  PLoS One       Date:  2013-07-17       Impact factor: 3.240

10.  HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds.

Authors:  Tom L G M van den Kerkhof; Steven W de Taeye; Brigitte D Boeser-Nunnink; Dennis R Burton; Neeltje A Kootstra; Hanneke Schuitemaker; Rogier W Sanders; Marit J van Gils
Journal:  Retrovirology       Date:  2016-07-07       Impact factor: 4.602

View more
  1 in total

1.  Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time.

Authors:  Lijie Wang; Shujia Liang; Jianhua Huang; Yibo Ding; Lin He; Yanling Hao; Li Ren; Meiling Zhu; Yi Feng; Abdur Rashid; Yue Liu; Shibo Jiang; Kunxue Hong; Liying Ma
Journal:  Front Cell Infect Microbiol       Date:  2022-03-17       Impact factor: 5.293

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.